Automation Takes Over Stem Cell Manufacturing Too, FDA Approves

| Technology

Become a contributor

Bookmark Econotimes

| Technology

Ads by AdKrypto

DNA sequencing is inadvertantly exacerbating social biases and inequalities

The resonances between Indigenous art and images captured by microscopes

Bitcoin Latest News & Update: Price of Bitcoin to Reach $8,000 to $12,000 in Coming Months?

Bitcoin Latest News & Update: SEC Close to Approving VanEck Bitcoin ETF?

Europe's set to blast off to Mercury – here's the rocket science

The argument from cyberspace for eliminating nuclear weapons

'Fallout 76' Latest News & Update: Titanic Failure as Expected, Burning Reviews Paint Apocalyptic Reception

3D concrete printing could free the world from boring buildings

Would a Space Force mean the end of NASA?

Bioenergy carbon capture: climate snake oil or the 1.5-degree panacea?

Alternative Torrent Sites That Can Replace The Piratebay During Recent Crackdowns

‘Fortnite’ Latest News & Update: Players Could Soon Fly Airplanes via Bumble Vehicle

‘Fallout 76’ Release Date, News & Update: Bethesda Gets Defensive About PC Hacks, Complains About Inaccurate Claims

'Frankenstein news': how new media recycles the mainstream press

'Red Dead Redemption 2' Latest News & Update: Anti-Feminists Celebrate Ability to Hurt Women in Game

Can your actions really save the planet? 'Planetary accounting' has the answer

How to read and learn from scientific literature, even if you're not an expert

©Elmin Media . All Rights Reserved.

Automation Takes Over Stem Cell Manufacturing Too, FDA Approves

Stem Cell Illustration.PublicDomainPictures/Pixabay

Tuesday, January 16, 2018 4:57 AM UTC

comments

When discussing stem cell research, most people would likely bring up scientists harvesting stem cells from living tissue. While this is certainly true, there is now a new method that would allow researchers to manufacture stem cells so that they have much more of it to work with. The U.S. Food and Drug Administration (FDA) recently approved the process employed by the Mayo Clinic, which actually automates the process.

In a press release, the Mayo Clinic describes both the process and implications of the FDA approval to stem cell research. Apparently, this allows the researchers to take the bone marrow of a donor and then produce a much higher quantity of stem cells that will then be used to advance research in regenerative medicine.

According to the medical director of Transfusion Medicine and the Human Cell Therapy Laboratory, Abba Zubair, this process is a huge boon for cases where the patient’s own stem cells are not enough to allow for treatment. These cases can often be a problem, mostly because harvesting stem cells is not exactly that easy.

“This may make treatments possible in cases where the patient’s own cells are not viable as therapy,” Dr. Zubair said. “In addition, because the cells can be produced in days instead of months, it may also make treatments available on short notice when they’re needed for acute care.”

As Futurism notes, stem cell research has already proven promising in a variety of treatment cases, addressing everything from arthritis to paralysis. By cranking up production of stem cells via an automated production method, not only will researchers have significantly more batches to work with, patients won’t have to wait for months to be treated.

On a side note, this process also highlights the huge advantages to automating the manufacturing process in the field of research and medicine. In these areas, robots are just taking over, and that might be for the best.

Ads by AdKrypto

EconoTimes 中文版经客时代已上线

深入了解中国动向

开始阅读 >

Econotimes China Edition

GET INSIGHTS IN CHINESE

READ NOW >

Editor's Picks

Can robots be ‘money doctors’?

I ran 100 miles in a day, this is what happened to my body

Why life insurance companies want your Fitbit data

Five hangover cures, reviewed by experts

Vegan dogs: should they go meat free?

Insatiable: an unhelpful portrayal of binge-eating disorder

Ads by AdKrypto

ET PRO
Market Data

Market-moving news and views, 24 hours a day >

ARGENTINA OCT 2018 PRIMARY BUD BAL FINAL INCREASE TO -16585.9 ARS VS PREV -22854.3 ARS

S&P, ON NETHERLANDS, SAYS POTENTIAL FINANCIAL, ECONOMIC SHOCKS COULD POTENTIALLY EMANATE FROM SLOWDOWN IN WORLD GROWTH/ADVERSE EFFECT ON NET TRADE FROM BREXIT

S&P SAYS THE NETHERLANDS RATINGS AFFIRMED AT 'AAA/A-1+'; OUTLOOK STABLE

FITCH SAYS AFFIRMS BULGARIA AT 'BBB'; OUTLOOK STABLE

FITCH AFFIRMS ROMANIA AT 'BBB-'; OUTLOOK STABLE

FOR THE WEEK, THE S&P FELL 1.61 PCT, THE DOW LOST 2.22 PCT, THE NASDAQ SHED 2.15 PCT

BRAZIL'S BOVESPA CLOSED AT 88,515.27, UP +2.96%

CANADA'S S&P/TSX COMPOSITE CLOSED AT 15,153.50, UP +0.06%

NASDAQ UNOFFICIALLY CLOSES DOWN 10.51 POINTS, OR 0.14 PERCENT, AT 7,248.52

S&P 500 UNOFFICIALLY CLOSES UP 6.59 POINTS, OR 0.24 PERCENT, AT 2,736.79

UNITED STATES SEP 2018 NET L-T FLOWS,INCL.SWAPS DECREASE TO 16.7 USD VS PREV 111.4 USD (REVISED FROM 111.5 USD)

DOW JONES UNOFFICIALLY CLOSES UP 129.68 POINTS, OR 0.51 PERCENT, AT 25,418.95

UNITED STATES SEP 2018 FOREIGN BUYING, T-BONDS DECREASE TO -11.5 USD VS PREV 63.1 USD

UNITED STATES SEP 2018 NET L-T FLOWS,EXSWAPS DECREASE TO 30.8 USD VS PREV 131.7 USD (REVISED FROM 131.8 USD)

BREXIT: FORMER UK BREXIT SECRETARY DAVID DAVIS SAYS PM MAY "WILL HAVE TO COME UP WITH ANOTHER ALTERNATIVE" TO BREXIT DEAL WITH EU - CNBC

BREXIT: FORMER UK BREXIT SECRETARY DAVID DAVIS SAYS PM MAY'S BREXIT DEAL WITH EU "WILL BE REJECTED" BY PARLIAMENT - CNBC

CFTC-SPECULATORS INCREASE CBOT US 5-YEAR TREASURY FUTURES NET SHORT POSITION BY 14,163 CONTRACTS TO 570,542 IN WEEK ON NOVEMBER 13

CFTC-SPECULATORS TRIM CBOT US 10-YEAR TREASURY FUTURES NET SHORT POSITION BY 205,991 CONTRACTS TO 333,195 IN WEEK ON NOVEMBER 13

CFTC-SPECULATORS INCREASE CBOT US 2-YEAR TREASURY FUTURES NET SHORT POSITION BY 28,894 CONTRACTS TO 362,374 IN WEEK ON NOVEMBER 13

Ads by AdKrypto

Most Popular

FxWirePro:USD/CHF Trade Idea

FxWirePro: EUR/USD trades above 20 day MA , jump till 1.1500 likely

FinTech Trends - JP Morgan's successful trial of blockchain adoption on settlements, IMF chief seems constructive on Singapore's FinTech symposium

FxWirePro: USD/CHF holds well above 1.000 level, good to buy on dips

Cryptocurrency Brief: Bitcoin tumbles to lowest in one year, altcoins follow suit, BCH/USD hit by hard fork

U.S.-China trade war underlines risk of concentrating production, triggers restructuring of supply chains: ANZ Research

FxWirePro Poll: No near-term relief for Bitcoin; could see small gains next year

Swedish krona likely to witness gradual uptrend vs euro on slower monetary policy normalization, says Commerzbank

Global Geopolitical Series: U.S. Commerce Department announces duties quartz products from China

Global Geopolitical Series: U.S. initiates duty investigations on Magnesium from Israel

Economics Monitor

November 16 21:00 UTC Released

UST Flows,Incl.Swaps

Actual

16.7 Bln USD

Forecast

111.5 Bln USD

November 16 21:00 UTC Released

USOverall Net Capital Flows

Actual

-29.1 Bln USD

Forecast

108.2 Bln USD

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

January 22 19:00 UTC 432341432341m

ARTrade Balance

Actual

Forecast

-1541 %

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

January 22 19:00 UTC 432341432341m

ARTrade Balance

Actual

Forecast

-1541 %

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

January 31 00:00 UTC 420521420521m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Bln AR bln ARS

EconoTimes

Ads by AdKrypto

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

深入了解中国动向

GET INSIGHTS IN CHINESE

Editor's Picks

Welcome to EconoTimes